Quick Answer
Arcutis Biotherapeutics, Inc. reported Cash and Equivalents of $53.64 million for fiscal year 2022.
Arcutis Biotherapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2022 | $53.64M | -44.4% |
| 2021 | $96.45M | +48.2% |
| 2020 | $65.08M | +2.8% |
| 2019 | $63.34M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $107.47M | +31.8% | +2.2% |
| June 30, 2023 | $105.11M | +70.9% | +29.1% |
| March 31, 2023 | $81.41M | +16.6% | +51.8% |
| December 31, 2022 | $53.64M | -44.4% | -34.2% |
| September 30, 2022 | $81.54M | +57.5% | +32.6% |
| June 30, 2022 | $61.51M | -31.0% | -11.9% |
| March 31, 2022 | $69.80M | -75.8% | -27.6% |
| December 31, 2021 | $96.45M | +48.2% | +86.3% |
- Arcutis Biotherapeutics, Inc. showed a decrease of -44.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2022 period, Arcutis Biotherapeutics, Inc.’s cash and equivalents has declined by 15.3% (from $63.34 million to $53.64 million).
- The most recent figure is from Arcutis Biotherapeutics, Inc.’s fiscal year 2022 report (Form 10-K), filed with the SEC on February 28, 2023.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: